STOCK TITAN

Vanguard (NYSE: BSX) discloses 111.1M-share holding in Boston Scientific

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Boston Scientific Corp disclosure: Vanguard Capital Management reports beneficial ownership of 111,127,205 shares of Common Stock, representing 7.47% of the class. The filing shows sole dispositive power over 111,127,205 shares and sole voting power over 14,715,637 shares, signed 04/29/2026.

Positive

  • None.

Negative

  • None.
Beneficially owned 111,127,205 shares Amount beneficially owned (Schedule 13G)
Percent of class 7.47% Percent of common stock class (Schedule 13G)
Sole voting power 14,715,637 shares Shares with sole power to vote
Sole dispositive power 111,127,205 shares Shares with sole power to dispose
Signature date 04/29/2026 Date the Schedule 13G was signed
Schedule 13G regulatory
"Item 1. (a) Name of issuer: Boston Scientific Corp"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially owned financial
"Item 4. (a) Amount beneficially owned: 111127205"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive power regulatory
"Item 4. (c)(iii) Sole power to dispose or to direct the disposition of: 111127205"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
sole voting power regulatory
"Item 4. (c)(i) Sole power to vote or to direct the vote: 14715637"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many Boston Scientific (BSX) shares does Vanguard Capital Management report owning?

Vanguard Capital Management reports beneficial ownership of 111,127,205 shares of Boston Scientific common stock. This ownership amount is stated in the Schedule 13G and is presented as 7.47% of the class in the filing signed on 04/29/2026.

What voting and dispositive powers does Vanguard report for BSX shares?

The filing states Vanguard has sole voting power over 14,715,637 shares and sole dispositive power over 111,127,205 shares. Shared voting and shared dispositive powers are reported as 0 in the Schedule 13G disclosure.

Does the Schedule 13G filing indicate Vanguard holds shares on behalf of others for BSX?

Yes. The filing explains Vanguard Capital Management exercises dispositive power over securities held by Vanguard funds and managed accounts, and notes these holdings include securities held for clients and Vanguard funds over which it exercises authority.

What percentage of Boston Scientific is represented by Vanguard's holding in this filing?

The Schedule 13G lists Vanguard Capital Management's position as 7.47% of Boston Scientific's outstanding common stock. That percentage is reported directly in the ownership section of the filing.

Who signed the Schedule 13G on behalf of Vanguard for BSX and when?

The filing is signed by Ashley Grim, titled Head of Global Fund Administration, with the signature date shown as 04/29/2026. The signature block appears at the end of the Schedule 13G excerpt.





101137107

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Capital Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:04/29/2026